Why the study?
Does antilipolytic treatment prevent ventricular fibrillation in patients with acute coronary syndromes?
Does antilipolytic treatment prevent ventricular fibrillation in patients with acute coronary syndromes?
Proposes the hypothesis that restricting free fatty acid availability via antilipolytic treatment may prevent ventricular fibrillation during acute myocardial ischemia.
Antilipolytic treatment should not yet be used for VF prevention in ACS; leaves open the hypothesis for prospective RCTs.
Fatal ventricular fibrillation is a common complication of acute coronary syndromes. Effective preventive measures are not available. Immediate restriction of free fatty acid availability should optimize ischemic myocardial metabolism, reduce ventricular vulnerability, and increase glucose utilization. Rapid inhibition of lipoprotein lipase activity will achieve this. The clinical effects of antilipolytic treatment require further study.
No takes yet. Share an insight, caveat, or question.
M.F. Oliver (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: